Recent Advances for Dynamic-Based Therapy of Atherosclerosis
Guanghao Wu,Guanye Yu,Meiling Zheng,Wenhui Peng,Lei Li
DOI: https://doi.org/10.2147/ijn.s402678
IF: 7.033
2023-07-14
International Journal of Nanomedicine
Abstract:Guanghao Wu, 1, &ast Guanye Yu, 2, &ast Meiling Zheng, 3, &ast Wenhui Peng, 2 Lei Li 4 1 School of Materials Science and Engineering, Beijing Institute of Technology, Beijing, 100081, People's Republic of China; 2 Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai, 200072, People's Republic of China; 3 Dongzhimen Hospital Beijing University of Chinese Medicine, Beijing, 101121, People's Republic of China; 4 National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lei Li, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Eastern District, Beijing, 100730, People's Republic of China, Tel +8613426328126, Fax +86 10 69158100, Email Guanghao Wu, School of Materials Science and Engineering, Beijing Institute of Technology, Beijing, 100081, People's Republic of China, Email Atherosclerosis (AS) is a chronic inflammatory disease, which may lead to high morbidity and mortality. Currently, the clinical treatment strategy for AS is administering drugs and performing surgery. However, advanced therapy strategies are urgently required because of the deficient therapeutic effects of current managements. Increased number of energy conversion-based organic or inorganic materials has been used in cancer and other major disease treatments, bringing hope to patients with the development of nanomedicine and materials. These treatment strategies employ specific nanomaterials with specific own physiochemical properties (external stimuli: light or ultrasound) to promote foam cell apoptosis and cholesterol efflux. Based on the pathological characteristics of vulnerable plaques, energy conversion-based nano-therapy has attracted increasing attention in the field of anti-atherosclerosis. Therefore, this review focuses on recent advances in energy conversion-based treatments. In addition to summarizing the therapeutic effects of various techniques, the regulated pathological processes are highlighted. Finally, the challenges and prospects for further development of dynamic treatment for AS are discussed. Keywords: atherosclerosis, nanomaterial, physiochemical, reactive oxygen species, energy conversion, therapy Cardiovascular disorders are the leading causes of morbidity and mortality worldwide. According to the latest report by the World Health Organization (WHO), approximately 32% of deaths are due to cardiovascular diseases (CVDs). 1 CVDs are a group of disorders of the heart and blood vessels. Approximately 45.1% of these cardiovascular disease-related deaths were caused by coronary artery disease. Atherosclerosis (AS) is a chronic inflammatory vascular disease. Smoking, alcoholism, high-diet, lack of exercise, and genetic predisposition are important factors in the development of AS. These factors increase blood lipid concentration and lipid deposits in vessel wall would lead to formation of atherosclerotic plaque and gradually induce stenosis and obstruction of blood flow. Rupture of atherosclerotic plaque produces lesions that result in acute myocardial infarction, sudden cardiac death, or other severe outcomes. 2,3 Until now, clinical treatments for AS focused on drugs and surgery; angioplasty and bypass grafting are the two main surgical interventions. 4,5 However, surgery is invasive and may induce thrombosis in the endarterectomized segment, which may increase the risk of thrombosis, bleeding, and restenosis. Statins, which are an important drug intervention, are thought to be important in the prevention of AS. These drugs could not only reduce cholesterol but also alleviate pro-inflammatory cytokine effects. Besides statins, some other drugs, such as proprotein convertase subtilisin/kexin type 9 inhibitors (Alirocumab and Evolocumab), could enhance low-density lipoprotein (LDL) degradation and promote lower cholesterol levels. 6 In addition, certain immunosuppressants (methotrexate and rapamycin) show a clear and promising impact in reducing atherosclerotic plaque sizes. However, there are still some limitations in terms of stability, targeting efficacy, toxicity, and production. Currently, the combination of nanotechnology and AS offers hope for the treatment of these diseases. Compared with traditional nano-therapies, energy conversion-based nano-therapy can not only leverage -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology